Antisense Therapeutics Advances ATL1102 Development with Encouraging Clinical Results

Antisense Therapeutics Limited (ASX: ADO) reported significant progress in advancing its lead drug candidate, ATL1102, targeting unmet needs in neuromuscular disorders. ATL1102, an antisense oligonucleotide, continues to show promise in clinical trials for Duchenne Muscular Dystrophy (DMD), with encouraging safety and efficacy indicators. The company highlighted patient improvements in muscle function and reduced inflammation, reinforcing ATL1102’s potential as a differentiated therapy. Antisense Therapeutics also strengthened its financial position through capital raising and funding initiatives to support ongoing research and regulatory activities. Additionally, the company is pursuing strategic collaborations and expanding its research focus to explore broader applications of antisense technology. Management emphasized their commitment to advancing ATL1102 toward late-stage clinical development while building long-term value for shareholders. The outlook remains positive as Antisense continues to address critical gaps in treatment options for rare neuromuscular diseases.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com